vinorelbine ebewe 10 mg/1 ml (as tartrate) injection vial
sandoz pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection, concentrated - excipient ingredients: nitrogen; water for injections - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.
vinorelbine ebewe 50 mg/5 ml (as tartrate) injection vial
sandoz pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection, concentrated - excipient ingredients: water for injections; nitrogen - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.
navelbine 20 mg
padagis israel agencies ltd, israel - vinorelbine as tartrate - capsules - vinorelbine as tartrate 20 mg - vinorelbine - vinorelbine - for the treatment of non small cell lung cancer. for the treatment of advanced breast cancer.
navelbine 30 mg
padagis israel agencies ltd, israel - vinorelbine as tartrate - capsules - vinorelbine as tartrate 30 mg - vinorelbine - vinorelbine - for the treatment of non small cell lung cancer. for the treatment of advanced breast cancer.
vinorelbine tartrate injection usp solution
sandoz canada incorporated - vinorelbine (vinorelbine tartrate) - solution - 10mg - vinorelbine (vinorelbine tartrate) 10mg - antineoplastic agents
vinorelbine injection, usp solution
mylan pharmaceuticals ulc - vinorelbine (vinorelbine tartrate) - solution - 10mg - vinorelbine (vinorelbine tartrate) 10mg - antineoplastic agents
vinorelbine injection, usp solution
fresenius kabi canada ltd - vinorelbine (vinorelbine tartrate) - solution - 10mg - vinorelbine (vinorelbine tartrate) 10mg - antineoplastic agents
vinorelbine 10mg/ml concentrate for solution for infusion concentrate for solution for infusion
accord healthcare limited - vinorelbine (vinorelbine tartrate) - concentrate for solution for infusion - 10mg/ml
vinorelbine 10mg/ml concentrate for solution for infusion concentrate for solution for infusion
accord healthcare limited - vinorelbine (vinorelbine tartrate) - concentrate for solution for infusion - 10mg/ml
vinorelbine- vinorelbine injection, solution
hospira, inc. - vinorelbine tartrate (unii: 253gqw851q) (vinorelbine - unii:q6c979r91y) - vinorelbine 10 mg in 1 ml - vinorelbine injection, usp is indicated: none pregnancy category d risk summary vinorelbine can cause fetal harm when administered to a pregnant woman. in animal reproduction studies in mice and rabbits, embryo and fetal toxicity were observed with administration of vinorelbine at doses approximately 0.33 and 0.18 times the human therapeutic dose, respectively. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to a fetus. animal data in a mouse embryofetal development study, administration of a single dose of vinorelbine at a dose level of 9 mg/m2 or greater (approximately 0.33 times the recommended human dose based on body surface area) was embryotoxic and fetotoxic. vinorelbine was embryotoxic and fetotoxic to pregnant rabbits when administered every 6 days during the period of organogenesis at doses of 5.5 mg/m2 (approximately 0.18 times the recommended human dose based on body surface area) or greater. at doses t